Introduction
Status epilepticus (SE) is the second most common neurological emergency, and frequently requires neurointensive care. SE persisting despite treatment with benzodiazepines and antiepileptic drugs is defined as refractory status epilepticus (RSE).
1 RSE frequently occurs in people without structural brain damage and carries a mortality rate of up to 40%. 1 While common causes of RSE have been extensively studied, uncommon causes such as autoimmune disorders and mitochondrial, genetic and metabolic diseases like folic acid (FA) deficiency have been explored less and are thus particularly challenging for the treating intensivist. 2 Several therapeutic and diagnostic strategies have been suggested for RSE, but none of these have been tested systematically. 3 Advanced neuromonitoring techniques allow online measurement of cerebral metabolic supply and demand. 4 Depending on molecular size and ionicity, several metabolites can be measured in the extracellular fluid of the human brain using cerebral microdialysis. In patients with non-convulsive status epilepticus (NCSE) following traumatic brain injury (TBI), an increase in lactate to pyruvate ratio, as indicator of metabolic distress, has been described. 5 In our report, the case of a patient with short bowel syndrome and systemic FA deficiency who developed RSE is described.
Case
A 47-year-old male was admitted to a primary care hospital because of recurrent complex partial seizures. The patient had no past medical history of epilepsy or traumatic brain injury, but had suffered severe abdominal trauma requiring partial colectomy (90 cm), partial jejunectomy and terminal ileum resection 5 months before admission. After surgery, he developed symptoms of short bowel syndrome including chronic diarrhoea and weight loss. At that time, folic acid and vitamin B12 levels were within normal ranges without oral replacement therapy. His medication included colestyramine, fenofibrate and a selective serotonin re-uptake inhibitor.
At the primary care hospital, contrast enhanced computed tomography (CT) of the brain was normal and electroencephalography (EEG) revealed focal slowing over the right temporal region. Anticonvulsive therapy with levetiracetam (2 g/day) was initiated. However, the patient deteriorated and required intubation for airway protection. He was transferred to our neurological intensive care unit (NICU) and given antiepileptic treatment including levetiracetam (3 g/day) and valproic acid (1.5 g/day). Laboratory findings revealed normochromic, normocytic anaemia (haemoglobin 10.2 g/dl; normal 13.0-17.7 g/dl; serum iron 3.5 mmol/l; normal 11-28 mmol/l). The admission EEG (Fig. 1A ) taken while the patient was on midazolam (0.6 mg/kg/h), ketamine (0.6 mg/kg/ h) and sufentanil (1.7 mg/kg/h), demonstrated continuous rhythmic epileptiform discharges over the right hemisphere. Intravenous phenytoin was administered at a loading dose of 12 mg/kg/h and continued with a maintenance dose of 9 mg/kg/day in order to achieve a serum concentration of 20 mg/ml. After 24 h of combined antiepileptic therapy and sedation, clinical findings and continuous EEG readings were suggestive of persisting NCSE (Fig. 1A) . Treatment with thiopental was initiated at a loading dose of 425 mg (5 mg/kg) and titrated to induce a burst-suppression EEG pattern (Fig. 1B) , which persisted for 5 days.
Cerebral magnetic resonance imaging (MRI) demonstrated cortical diffusion restriction of the entire right hemisphere E-mail addresses: Alois.Schiefecker@i-med.ac.at, alois.schiefecker@gmx.at (A.J. Schiefecker).
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Seizure j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y s e i z including the ipsilateral thalamus and the caudate nucleus ( Fig. 2A) , but no abnormal contrast enhancement or structural brain lesion. Cerebrospinal fluid (CSF) analysis was unremarkable and polymerase chain reaction for herpes simplex virus, varicella zoster virus and cytomegalovirus was negative, as was serology for neurotropic arthropod-borne viruses. Serum and CSF testing for antithyroid antibodies, onconeuronal antibodies (Hu, Yo, Ma2, CV2/CRMP-5, Amphiphysin and Ri) and antibodies against glutamate receptors and voltage gated potassium channels were negative.
Two days after admission, a microdialysis catheter was implanted into the right frontal white matter (Fig. 2C ) in order to monitor brain metabolism. Cerebral microdialysis was approved by the local ethics committee, details of which are given in supplementary methods.
During the entire monitoring period, cerebral lactate levels were normal (<4.0 mmol/l 4 ) and lactate to pyruvate ratio was below 40. Initially elevated glutamate levels (74.65 mmol/l; normal 16 AE 16 mmol/l 4 ) significantly decreased over time. Before intravenous FA replacement therapy on the second day after admission, serum FA levels were 3.4 mg/l (normal 4.6-18.7 mg/ l) and retrospectively evaluated brain FA levels were 2.2 mg/l.
Assuming an FA recovery rate of 21% (see supplementary methods), post-hoc estimation of brain FA level was 10.4 mg/l. On the sixth day after admission, FA levels increased to 11.6 mg/l (+241%) in serum and to 3.9 mg/l (+77%) in the microdialysate of the brain.
Nine days after admission, EEG demonstrated diffuse theta slowing without ictal discharges (Fig. 1C) . Within the next 24 h, the patient was extubated. There were no electrographic or clinical seizures and imaging findings improved (Fig. 2C and D) .
The patient was discharged to a neurological rehabilitation unit 21 days after admission. His discharge treatment consisted of valproic acid (3 g/day), phenytoin (500 mg/day), lacosamid (400 mg/day), levetiracetam (3 g/day) and oral FA replacement therapy (5 mg/day). He remained seizure-free during the following 12 months and recovered to an independent state, returning to his previous work. His current medication includes levetiracetam (1.5 g/day), lacosamid (400 mg/day) and oral folic acid replacement therapy (5 mg/day).
Discussion
To our knowledge, this case of a patient with FA deficiency and RSE is the first in vivo investigation of human brain FA levels during seizure activity and after intravenous replacement therapy.
Our patient suffered from short bowel syndrome following partial colectomy and small intestine resection. Typical clinical signs and symptoms of short bowel syndrome include chronic diarrhoea resulting in intestinal malabsorption. This may well explain FA deficiency in our patient.
FA transport into the central nervous system is adenosine triphosphate-dependent and mainly occurs via specific transporters at the choroid plexus. 6 There is a correlation between FA levels in serum and in CSF. 6 However, no data has been published on cerebral extracellular FA levels in humans. Our report describes a clear response of cerebral FA levels to intravenous replacement therapy. We observed a FA brain to serum ratio of 3, with FA levels increasing more in serum than in brain after intravenous replacement therapy. These findings are consistent with a previous study on rodents.
7 RSE due to an inborn error of FA metabolism has been previously reported in paediatric patients. 8 FA as methyl donor plays an important role in cerebral mitochondrial function and nucleic acid synthesis. 9 Moreover, a decrease of brain oxygenation has been linked to FA deficiency, 10 which may influence seizure activity.
A recent report of a patient with status epilepticus and hypoxic brain injury demonstrated that multimodal neuromonitoring, including cerebral microdialysis, may be a feasible method for evaluating secondary brain injury related to seizure activity. 11 As several processes deleterious to the human brain may occur in the course of RSE, monitoring cerebral metabolism may be helpful for interpretation of clinical and electrographic data. 11 A lactate to pyruvate ratio above 40 indicates a mismatch between cerebral energy supply and demand, and has been described in patients with status epilepticus after TBI 5 and cardiac arrest. 11 We observed a lactate to pyruvate ratio below 40, which could be explained by the fact that we started cerebral microdialysis after initiation of barbiturate anaesthesia. Furthermore, the microdialysis catheter was placed in the cortico-medullar region 5 mm adjacent to diffusion restrictions without structural lesions or brain oedema on MRI. Seizures due to metabolic disorders are commonly associated with generalized epileptic activity, but may also be associated with unilateral EEG-findings. 12, 13 The intensity of therapy in RSE is guided by continuous EEGreadings. The target of the therapy is either the cessation of electrographic seizures or the achievement of a burst suppression pattern on surface EEG.
14 Alongside other anaesthetics, we used intravenous ketamine in our patient. Ketamine may have several beneficial effects in the treatment of SE. 3, 15 First, ketamine has superior haemodynamic properties compared to propofol. Second, ketamine as a non-competitive NMDA-receptor antagonist might play a role in effective treatment of prolonged electrographic seizures. We observed a decrease in levels of cerebral glutamate over time. However, a causative relationship between cerebral glutamate metabolism and ketamine treatment cannot be concluded from this single observation. Diffusion-weighted (DW)-MRI demonstrated hyperintense signal abnormalities of the right cortex, caudate nucleus and thalamus with partial resolution at follow-up imaging. DW-MRI signal abnormalities following SE may involve the hippocampus, cortical and thalamic structures and can persist for months. 16 Important differential diagnoses of SE with MRI abnormalities include Wernicke's encephalopathy or limbic encephalitis. Herpes simplex encephalitis was excluded by PCR and thiamine levels were normal. Limbic encephalitis also has additional clinical features such as subacute amnestic syndrome or psychiatric symptoms. Moreover, the combination of absent onconeuronal, NMDA and VGKC antibodies combined with unremarkable CSFfindings makes the diagnosis of limbic encephalitis unlikely.
In conclusion, cerebral microdialysis is a feasible method for monitoring brain metabolism during RSE. Furthermore, we demonstrated that folic acid can be measured in cerebral microdialysate and that brain folic acid levels were comparable to results of previous animal studies. Although causality cannot be proven, FA deficiency may have influenced the course of RSE in our patient.
